These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 17111119)

  • 21. Sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: results of a multicenter phase II study of the northeastern German society of gynecological oncology.
    Oskay-Ozcelik G; Chekerov R; Sommer H; Keil E; Einenkel J; Pfisterer J; Lorenz-Schlüter C; Lichtenegger W; Camara O; Sehouli J
    Gynecol Oncol; 2010 Mar; 116(3):317-22. PubMed ID: 19959213
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix.
    Fiorica J; Holloway R; Ndubisi B; Orr J; Grendys E; Boothby R; DeCesare S; LaPolla J; Hoffman M; Patel J
    Gynecol Oncol; 2002 Apr; 85(1):89-94. PubMed ID: 11925125
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
    Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
    Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
    Pignata S; Breda E; Scambia G; Pisano C; Zagonel V; Lorusso D; Greggi S; De Vivo R; Ferrandina G; Gallo C; Perrone F
    Crit Rev Oncol Hematol; 2008 Jun; 66(3):229-36. PubMed ID: 18243011
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.
    Rose PG; Gordon NH; Fusco N; Fluellen L; Rodriguez M; Ingalls ST; Hoppel CL
    Gynecol Oncol; 2000 Aug; 78(2):228-34. PubMed ID: 10926808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer.
    Bos AM; De Vos FY; de Vries EG; Beijnen JH; Rosing H; Mourits MJ; van der Zee AG; Gietema JA; Willemse PH
    Eur J Cancer; 2005 Mar; 41(4):539-48. PubMed ID: 15737558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer.
    Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
    Gynecol Oncol; 2000 Oct; 79(1):116-9. PubMed ID: 11006042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma.
    Rose PG; Smrekar M; Fusco N
    Gynecol Oncol; 2005 Feb; 96(2):296-300. PubMed ID: 15661211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG study.
    Hochster HS; Plimack ER; Mandeli J; Wadler S; Runowicz C; Goldberg G; Speyer J; Wallach R; Muggia F;
    Gynecol Oncol; 2006 Feb; 100(2):324-9. PubMed ID: 16253316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
    Swisher EM; Mutch DG; Rader JS; Elbendary A; Herzog TJ
    Gynecol Oncol; 1997 Sep; 66(3):480-6. PubMed ID: 9299264
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.
    Seiden MV; Ng SW; Supko JG; Ryan DP; Clark JW; Lynch T; Huang KC; Kwiatkowski D; Skarin A; Eder JP
    Clin Cancer Res; 2002 Mar; 8(3):691-7. PubMed ID: 11895897
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: results of a single-institutional phase II study.
    Kang H; Kim TJ; Lee YY; Choi CH; Lee JW; Bae DS; Kim BG
    Gynecol Oncol; 2009 Aug; 114(2):210-4. PubMed ID: 19446320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carboplatin and short-infusion paclitaxel in high-risk and advanced-stage ovarian carcinoma.
    Coleman RL; Bagnell KG; Townley PM
    Cancer J Sci Am; 1997; 3(4):246-53. PubMed ID: 9263631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
    Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer.
    Herzog TJ; Powell MA; Rader JS; Gibb R; Mutch DG
    Gynecol Oncol; 2006 Nov; 103(2):637-41. PubMed ID: 16781766
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Topotecan and ifosfamide as salvage treatment in advanced ovarian cancer.
    Chiara S; Tognoni A; Pastrone I; Tomasello L; Brema F; Di Costanzo G; Folco U; Pronzato P;
    Gynecol Oncol; 2004 May; 93(2):474-8. PubMed ID: 15099965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer.
    Safra T; Menczer J; Bernstein R; Shpigel S; Inbar MJ; Grisaru D; Golan A; Levy T
    Gynecol Oncol; 2007 Apr; 105(1):205-10. PubMed ID: 17239430
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer.
    Lin CC; Cheng AL; Hsu CH; Lu YS; Hsu C; Yeh KH; Wu CY; Huang CS; Yang CH
    Anticancer Res; 2007; 27(1B):641-5. PubMed ID: 17348454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer.
    Gronlund B; Høgdall C; Hansen HH; Engelholm SA
    Gynecol Oncol; 2001 Oct; 83(1):128-34. PubMed ID: 11585424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.